메뉴 건너뛰기




Volumn 21, Issue 1, 2007, Pages 29-36

Long-term pharmacological activation of PPARγ does not prevent left ventricular remodeling in dogs with advanced heart failure

Author keywords

Drugs; Heart failure; Hemodynamics; Remodeling

Indexed keywords

CYTOKINE; GW 347845; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P21; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 34247137270     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6003-9     Document Type: Article
Times cited : (7)

References (45)
  • 2
    • 10544229796 scopus 로고    scopus 로고
    • Activation of the nuclear receptor peroxisome proliferators-activated receptor gamma promotes brown adipocyte differentiation
    • Tai TA, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, et al. Activation of the nuclear receptor peroxisome proliferators-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem 1996;271:20090-114.
    • (1996) J Biol Chem , vol.271 , pp. 20090-20114
    • Tai, T.A.1    Jennermann, C.2    Brown, K.K.3    Oliver, B.B.4    MacGinnitie, M.A.5    Wilkison, W.O.6
  • 3
    • 0028598170 scopus 로고
    • Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat
    • Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994;43:1435-40.
    • (1994) Diabetes , vol.43 , pp. 1435-1440
    • Lee, M.K.1    Miles, P.D.2    Khoursheed, M.3    Gao, K.M.4    Moossa, A.R.5    Olefsky, J.M.6
  • 4
    • 0037459356 scopus 로고    scopus 로고
    • PPARs of the heart
    • Kelly DP. PPARs of the heart. Circ Res 2003;92:482-4.
    • (2003) Circ Res , vol.92 , pp. 482-484
    • Kelly, D.P.1
  • 5
  • 6
    • 0031888958 scopus 로고    scopus 로고
    • PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
    • Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-6.
    • (1998) Nature , vol.391 , pp. 82-86
    • Jiang, C.1    Ting, A.T.2    Seed, B.3
  • 7
    • 0034730794 scopus 로고    scopus 로고
    • Peroxisome proliferators-activated receptor activators inhibit lipoplysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes
    • Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, et al. Peroxisome proliferators-activated receptor activators inhibit lipoplysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000;87:596-602.
    • (2000) Circ Res , vol.87 , pp. 596-602
    • Takano, H.1    Nagai, T.2    Asakawa, M.3    Toyozaki, T.4    Oka, T.5    Komuro, I.6
  • 8
    • 0141788713 scopus 로고    scopus 로고
    • Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins
    • Lee TM, Chou TF. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am J Physiol Heart Circ Physiol 2003;285:H1650-9.
    • (2003) Am J Physiol Heart Circ Physiol , vol.285
    • Lee, T.M.1    Chou, T.F.2
  • 9
    • 0034646419 scopus 로고    scopus 로고
    • Troglitazone improves recovery of left ventricular function after regional ischemia in pigs
    • Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000;101:1165-71.
    • (2000) Circulation , vol.101 , pp. 1165-1171
    • Zhu, P.1    Lu, L.2    Xu, Y.3    Schwartz, G.G.4
  • 11
    • 13944284526 scopus 로고    scopus 로고
    • PPARγ activation fails to provide myocardial protection in ischemia and reperfusion in pigs
    • Xu Y, Gen M, Lu L, et al. PPARγ activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 2005;288:H1314-23.
    • (2005) Am J Physiol Heart Circ Physiol , vol.288
    • Xu, Y.1    Gen, M.2    Lu, L.3
  • 12
    • 0037453063 scopus 로고    scopus 로고
    • Glitazones and heart failure: Critical appraisal for the clinician
    • Wang CH, Weisel RD, Liu PP, Fedak PWM, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
    • (2003) Circulation , vol.107 , pp. 1350-1354
    • Wang, C.H.1    Weisel, R.D.2    Liu, P.P.3    Fedak, P.W.M.4    Verma, S.5
  • 13
    • 10744221639 scopus 로고    scopus 로고
    • Thiazolidine use, fluid retention, and congestive heart failure. A consensus statement from the Ameicarn Heart Association and the American Diabetes Association
    • Nesto RW, Ball D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidine use, fluid retention, and congestive heart failure. A consensus statement from the Ameicarn Heart Association and the American Diabetes Association. Diabetes Care 2004;27:256-63.
    • (2004) Diabetes Care , vol.27 , pp. 256-263
    • Nesto, R.W.1    Ball, D.2    Bonow, R.O.3    Fonseca, V.4    Grundy, S.M.5    Horton, E.S.6
  • 14
    • 0025865760 scopus 로고
    • A canine model of chronic heart failure produced by multiple sequential coronary microembolizations
    • Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-84.
    • (1991) Am J Physiol , vol.260
    • Sabbah, H.N.1    Stein, P.D.2    Kono, T.3    Gheorghiade, M.4    Levine, T.B.5    Jafri, S.6
  • 15
    • 0028261043 scopus 로고
    • Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction
    • Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
    • (1994) Circulation , vol.89 , pp. 2852-2859
    • Sabbah, H.N.1    Shimoyama, H.2    Kono, T.3    Gupta, R.C.4    Sharov, V.G.5    Scicli, G.6    Levine, T.B.7
  • 16
    • 0033864582 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor r ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
    • Li AC, Brown KK, Silvestre MJ, Wilson TM, Palinski W, Glass C. Peroxisome proliferator-activated receptor r ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523-31.
    • (2000) J Clin Invest , vol.106 , pp. 523-531
    • Li, A.C.1    Brown, K.K.2    Silvestre, M.J.3    Wilson, T.M.4    Palinski, W.5    Glass, C.6
  • 17
    • 16844378356 scopus 로고
    • Pressure measurement
    • Grossman W, Baim DS editors, Philadelphia: Lea & Febiger;
    • Grossman W: Pressure measurement. In: Grossman W, Baim DS editors. Cardiac catheterization, angiography, and intervention. Philadelphia: Lea & Febiger; 1991. p. 123.
    • (1991) Cardiac catheterization, angiography, and intervention , pp. 123
    • Grossman, W.1
  • 18
    • 0031003230 scopus 로고    scopus 로고
    • Effects of angiotension-converting enzyme inhibitors and angiotension II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotension II type 2 receptors
    • Liu Yh, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotension-converting enzyme inhibitors and angiotension II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotension II type 2 receptors. J Clin Invest 1997;99:1926-35.
    • (1997) J Clin Invest , vol.99 , pp. 1926-1935
    • Liu, Y.1    Yang, X.P.2    Sharov, V.G.3    Nass, O.4    Sabbah, H.N.5    Peterson, E.6
  • 19
    • 0035942264 scopus 로고    scopus 로고
    • Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST)
    • Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-9.
    • (2001) Circulation , vol.103 , pp. 2055-2059
    • Deswal, A.1    Petersen, N.J.2    Feldman, A.M.3    Young, J.B.4    White, B.G.5    Mann, D.L.6
  • 20
    • 0029871896 scopus 로고    scopus 로고
    • Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
    • Apr
    • Torre-Aminone G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27 5:1201-6, Apr.
    • (1996) J Am Coll Cardiol , vol.27 , Issue.5 , pp. 1201-1206
    • Torre-Aminone, G.1    Kapadia, S.2    Benedict, C.3    Oral, H.4    Young, J.B.5    Mann, D.L.6
  • 21
    • 0033614816 scopus 로고    scopus 로고
    • Safety and efficacy of a soluble p75 tumor necrosis factor receptor (etanercept) in patients with advanced heart failure
    • Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6.
    • (1999) Circulation , vol.99 , pp. 3224-3226
    • Deswal, A.1    Bozkurt, B.2    Seta, Y.3    Parilti-Eiswirth, S.4    Hayes, F.A.5    Blosch, C.6
  • 22
    • 0035957036 scopus 로고    scopus 로고
    • Results of targeted anti-tumor necrosis factory therapy with entanercept (ENBREL) in patients with advanced heart failure
    • Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factory therapy with entanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7.
    • (2001) Circulation , vol.103 , pp. 1044-1047
    • Bozkurt, B.1    Torre-Amione, G.2    Warren, M.S.3    Whitmore, J.4    Soran, O.Z.5    Feldman, A.M.6
  • 23
    • 0032507428 scopus 로고    scopus 로고
    • Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy
    • Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-3.
    • (1998) Lancet , vol.351 , pp. 1091-1093
    • Sliwa, K.1    Skudicky, D.2    Candy, G.3    Wisenbaugh, T.4    Sareli, P.5
  • 24
    • 11144355760 scopus 로고    scopus 로고
    • Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
    • Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
    • (2004) Circulation , vol.109 , pp. 1594-1602
    • Mann, D.L.1    McMurray, J.J.2    Packer, M.3    Swedberg, K.4    Borer, J.S.5    Colucci, W.S.6
  • 25
    • 0031886864 scopus 로고    scopus 로고
    • The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
    • Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
    • (1998) Nature , vol.391 , pp. 79-82
    • Ricote, M.1    Li, A.C.2    Wilson, T.M.3    Kelly, C.J.4    Glass, C.K.5
  • 26
    • 0032972793 scopus 로고    scopus 로고
    • Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts
    • Shimoyama M, Ogino K, Tanaka Y, Ikeda T, Hisatome I. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999;48:609-15.
    • (1999) Diabetes , vol.48 , pp. 609-615
    • Shimoyama, M.1    Ogino, K.2    Tanaka, Y.3    Ikeda, T.4    Hisatome, I.5
  • 27
    • 0031054699 scopus 로고    scopus 로고
    • Cardiac and glycemic benefits of troglitazone treatment in NIDDM: The troglitazone study group
    • Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the troglitazone study group. Diabetes 1997;46:433-9.
    • (1997) Diabetes , vol.46 , pp. 433-439
    • Ghazzi, M.N.1    Perez, J.E.2    Antonucci, T.K.3    Driscoll, J.H.4    Huang, S.M.5    Faja, B.W.6
  • 28
    • 0033520304 scopus 로고    scopus 로고
    • Peroxisome proliferators-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
    • Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferators-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402.
    • (1999) Circ Res , vol.85 , pp. 394-402
    • Delerive, P.1    Martin-Nizard, F.2    Chinetti, G.3    Trottein, F.4    Fruchart, J.C.5    Najib, J.6
  • 30
    • 0037066014 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo
    • Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubuto N, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002;105:1240-6.
    • (2002) Circulation , vol.105 , pp. 1240-1246
    • Asakawa, M.1    Takano, H.2    Nagai, T.3    Uozumi, H.4    Hasegawa, H.5    Kubuto, N.6
  • 32
    • 0034598979 scopus 로고    scopus 로고
    • Troglitazone does not initiate hypertrophy but can sensitize cardiomyocytes to grow effects the serum
    • Bell D, McDermott BJ. Troglitazone does not initiate hypertrophy but can sensitize cardiomyocytes to grow effects the serum. Eur J Pharmacol 2000;390:237-44.
    • (2000) Eur J Pharmacol , vol.390 , pp. 237-244
    • Bell, D.1    McDermott, B.J.2
  • 34
    • 0033605677 scopus 로고    scopus 로고
    • Peroxisome proliferators- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
    • Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferators- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.
    • (1999) J Biol Chem , vol.274 , pp. 9116-9121
    • Xin, X.1    Yang, S.2    Kowalski, J.3    Gerritsen, M.E.4
  • 35
    • 0033546190 scopus 로고    scopus 로고
    • Endothelial cell apoptosis induced by the peroxisome proliferators-activated receptor (PPAR) ligand 15-deoxy-Delta 12, 14-prostaglandin J2
    • Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferators-activated receptor (PPAR) ligand 15-deoxy-Delta 12, 14-prostaglandin J2. J Biol Chem 1999;274:17042-8.
    • (1999) J Biol Chem , vol.274 , pp. 17042-17048
    • Bishop-Bailey, D.1    Hla, T.2
  • 36
    • 0037453063 scopus 로고    scopus 로고
    • Glitazones and heart failure: Critical appraisal for the clinician
    • Wang CH, Weisel RD, Liu PP, Fedak PWM, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
    • (2003) Circulation , vol.107 , pp. 1350-1354
    • Wang, C.H.1    Weisel, R.D.2    Liu, P.P.3    Fedak, P.W.M.4    Verma, S.5
  • 37
    • 0036218614 scopus 로고    scopus 로고
    • Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure
    • Wooltron E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Medical Assoc J 2002;166:219.
    • (2002) Can Medical Assoc J , vol.166 , pp. 219
    • Wooltron, E.1
  • 38
    • 0344230806 scopus 로고    scopus 로고
    • Tolerability profile of pioglitazone in combination with a sulfonyluria or metformin in controlled clinical trials
    • Belcher GL, Michel JL. Tolerability profile of pioglitazone in combination with a sulfonyluria or metformin in controlled clinical trials. Diabetes 2001;49 Suppl 2:A416.
    • (2001) Diabetes , vol.49 , Issue.SUPPL. 2
    • Belcher, G.L.1    Michel, J.L.2
  • 39
    • 0000469315 scopus 로고    scopus 로고
    • Adverse events with pioglitazone
    • Aronoff SL. Adverse events with pioglitazone. Diabetes 2000;49 Suppl 1:A340.
    • (2000) Diabetes , vol.49 , Issue.SUPPL. 1
    • Aronoff, S.L.1
  • 40
    • 0036833805 scopus 로고    scopus 로고
    • A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes
    • St. John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64.
    • (2002) Diabetes Care , vol.25 , pp. 2058-2064
    • St. John Sutton, M.1    Rendell, M.2    Dandona, P.3    Dole, J.F.4    Murphy, K.5    Patwardhan, R.6
  • 41
    • 0034406481 scopus 로고    scopus 로고
    • PPAR-gamma agonists: Therapeutic role in diabetes, inflammation and cancer
    • Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-74.
    • (2000) Trends Pharmacol Sci , vol.21 , pp. 469-474
    • Murphy, G.J.1    Holder, J.C.2
  • 42
    • 0033741281 scopus 로고    scopus 로고
    • Expression of peroxisome proliferators-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists
    • Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, et al. Expression of peroxisome proliferators-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000;83:1394-400.
    • (2000) Br J Cancer , vol.83 , pp. 1394-1400
    • Sato, H.1    Ishihara, S.2    Kawashima, K.3    Moriyama, N.4    Suetsugu, H.5    Kazumori, H.6    Okuyama, T.7
  • 43
    • 0032746173 scopus 로고    scopus 로고
    • A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
    • Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
    • (1999) J Clin Invest , vol.104 , pp. 383-389
    • Su, C.G.1    Wen, X.2    Bailey, S.T.3    Jiang, W.4    Rangwala, S.M.5    Keilbaugh, S.A.6
  • 44
    • 0033925031 scopus 로고    scopus 로고
    • 15-deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
    • Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, et al. 15-deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000;106:189-97.
    • (2000) J Clin Invest , vol.106 , pp. 189-197
    • Kawahito, Y.1    Kondo, M.2    Tsubouchi, Y.3    Hashiramoto, A.4    Bishop-Bailey, D.5    Inoue, K.6
  • 45
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial
    • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89.
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3    Erdmann, E.4    Massi-Benedetti, M.5    Moules, I.K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.